Posts - CLL Support | HealthUnlocked

Hi There, Finnish 4th course of Rituximab over a week ago,would like to know what to expect after it,ha sore throat,mouthfuls of ulcers,getting pain down in my...

Administrator•3 months ago

11 Replies

Want to take advantage of all our features? Just log in!

What to expect after finishing course of rituximab

Hi There, Finnish 4th course of Rituximab over a week ago,would like to know wha...

Jsceltic67

•3 months ago

A Young Mom Confronts “Skyrocketing White Blood Cell Counts”...

Brave young kiwi woman

Kiwidi

•4 months ago

3 Replies

obinutuzamab fatigue

I had my second infusion of Obi Friday. All went well with no reaction. Had some sleeping issues from steroids but that has passed. Curious if people...

I had my second infusion of Obi Friday. All went well with no reaction. Had so...

Nbk59ct

•5 months ago

3 Replies

MRD - Flow test compared to clonoSEQ

I just got this result after a year of Acalabrutinib and Venetoclax on the Majic trial. I'm currently waiting for the clonoSEQ MRD6 results. Below...

I just got this result after a year of Acalabrutinib and Venetoclax on the Majic...

JDG45

•5 months ago

uMRD is great, but for a majority that reach it, CLL will inevitably reoccur, and at that point, because of the strong selective pressures put on the surviving...

uMRD question

uMRD is great, but for a majority that reach it, CLL will inevitably reoccur, an...

PulsedTherapy

•6 months ago

120 Replies

Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Phase 2 CLL2-BAAG trial results from the German CLL Study Group

Some very encouraging news for those with unmutated IGHV and/or TP53 aberrations, who are wondering how they will fare with a subsequent treatment. This phase...

Some very encouraging news for those with unmutated IGHV and/or TP53 aberrations...

Administrator•7 months ago

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investigated GLPG5201, a CD19 CAR T-cell therapy, in relapsed/refractory (R/R)...

Encouraging phase 1 trial results for GLPG5201, a CAR T-cell therapy

Introducing the Phase I EUPLAGIA-1 study (EudraCT 2021-003815-25), which investi...

bennevisplace

•7 months ago

For the Majic trail, arm "A", I would like to know if anyone has completed the first 15 cycles of Acalabrutinib and Venetoclax. Has your bone marrow testing...

Majic trial arm "A"

For the Majic trail, arm "A", I would like to know if anyone has completed the f...

JDG45

•8 months ago

12 Replies

A potential game-changer for CAR T cell therapy: mutations in cancer engineered to beat cancer

CAR T therapy has been successful in some acute blood cancers. Response rates, however, are considerably lower in CLL and solid tumours, with T cell exhaustion...

CAR T therapy has been successful in some acute blood cancers. Response rates, h...

bennevisplace

•10 months ago

It’s official I have completed 6 years of taking part in the I. & R Arm of the Flair Trial today . I started on 28th January 2018 and I took my last dose of...

Flair Trial Completed

It’s official I have completed 6 years of taking part in the I. & R Arm of the...

Sanphil

•10 months ago

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating to test the efficacy and safety of AZD3152 as a component of a reformulated...

Current SUPERNOVA Clinical Trial for Reformulated EVUSHELD for preventing COVID-19 infection for immune-impaired individuals

A Phase II sub-study of SUPERNOVA clinical trial (2023) is currently operating t...

Classicaljazz

•10 months ago

5 Replies

How you can help make ibrutinib plus venetoclax fixed duration therapy a reality for Australians with previously untreated CLL

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Scheme (PBS) unless it has first been recommended by the Pharmaceutical Benefits...

In Australia, no new medicine can be listed on the Pharmaceutical Benefits Schem...

CLLerinOz

Administrator•1 year ago

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/jLVV3dtGc2BI8hLRqrMq892g "Although the overall benefits of these products...

Drugs.com FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed (CAR) T cell Immunotherapies

https://newsletters.drugs.com/l/HXdBAPWpNu8924jmwPHb3VvA/LQCEtlvhvlnyLNQoIP4Gfw/...

JerrysGirl3

•1 year ago

2 Replies

A new kid on the block? Nemtabrutinib

Hi All, There is a new targeted drug in Clinical Trials that may offer a new treatment option for us CLLers—Nemtabrutinib. For the entire article on this...

Hi All, There is a new targeted drug in Clinical Trials that may offer a new tr...

Varney

•1 year ago

18 Replies

Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on papers selected from "A comprehensive search on PubMed,...

The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation ...

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia added venetoclax to its listings for the retreatment of CLL/SLL in those whose...

Administrator•1 year ago

17 Replies

Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL

In more good news, today the Pharmaceutical Benefits Scheme (PBS) in Australia a...

CLLerinOz

Administrator•1 year ago

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a first line therapy for the treatment of CLL/SLL. As well as being available...

Zanubrutinib has been listed on the Pharmaceutical Benefits Scheme in Australia as a first line treatment for CLL/SLL

Australia's Pharmaceutical Benefits Scheme (PBS) today added Zanubrutinib as a f...

CLLerinOz

Administrator•1 year ago

We've had several posts in the last 24 hours about the U.S. government's plans to negotiate a price for ibrutinib. I mentioned...

Largest real world study of acalabrutinib and ibrutinib over 3 years, shows acalabrutinib has improved discontinuation rates

We've had several posts in the last 24 hours about the U.S. government's plans t...

Making my exercise "rounds" at the hospital It was a nice long run and far exceeded the average duration of response to CAR-T in CLL, but as we all...

Administrator•1 year ago

2 Replies

Starting therapy 5 yrs post CAR-T with another immunotherapy trial, now epcoritamab

Making my exercise "rounds" at the hospital It was a nice long run and far exce...

bkoffman

CLL CURE Hero•1 year ago

63 Replies

Now showing on Vjhemonc CLL channel, Epcoritamab for Richter's, identifying high risk CLL, Pirtobrutinib Genomic Evolution, HOVON 141/VISION

The latest videos on the CLL channel https://www.vjhemonc.com/subject/chronic-lymphocytic-leukemia/#latest-videos. complement some of the recent posts on new...

The latest videos on the CLL channel https://www.vjhemonc.com/subject/chronic-ly...

Many of us are aware of the risk of tumor lysis syndrome (TLS) when we commence treatment, particularly with venetoclax and that the purpose of the venetoclax...

Administrator•1 year ago

9 Replies

Tumor Lysis Syndrome: What ( CLL ) Patients Need to Know (Leukemia and Lymphoma Society podcast)

Many of us are aware of the risk of tumor lysis syndrome (TLS) when we commence ...

Administrator•2 years ago

My brother was diagnosed with CLL just over 2 years ago. He’s about to start treatment with obinutuzumab and venetoclax. He’s on a few meds for blood pressure...

Brother about to start treatment, advice please

My brother was diagnosed with CLL just over 2 years ago. He’s about to start tre...

EricSun

•2 years ago

This is something that some of our USA members have discussed with their doctors and it looks like the logic is correct. "Patients (pts) receiving...

Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patient with High Risk CLL Who Have Been on Ibrutinib More Than a Year

This is something that some of our USA members have discussed with their doctors...

Jm954

Administrator•2 years ago

An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6 million to 6.6 million presumptive atrial fibrillation cases are...

1.5 million atrial fibrillation cases may be undiagnosed in US (prevalence estimate of 11%)

An analysis of five U.S. medical claims databases suggests as many as 23% of 5.6...

Administrator•2 years ago